Gilead Competitors

Stocks Brazil . 
Stock . Gilead Sciences
GILD34 Stock  BRL 262.19  3.12  1.20%   
Gilead Sciences competes with Energisa, BTG Pactual, Plano Plano, Companhia Habitasul, and Procter Gamble; as well as few others. The company operates under Healthcare sector and is part of Drug Manufacturers - Major industry. Analyzing Gilead Sciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Gilead Sciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Gilead Sciences Correlation with its peers.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Gilead Sciences competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
260.73262.19263.65
Details
Intrinsic
Valuation
LowRealHigh
235.97302.66304.12
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Gilead Sciences. Your research has to be compared to or analyzed against Gilead Sciences' peers to derive any actionable benefits. When done correctly, Gilead Sciences' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Gilead Sciences.

Gilead Sciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Gilead Sciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Gilead and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Gilead Sciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
BTLG11
+ 0.88
ENGI11
HBTS5
+ 0.87
ENGI11
HBTS5
+ 0.83
BTLG11
BEWZ39
+ 0.82
E1RI34
E1RI34
+ 0.78
PLPL3
BEWZ39
+ 0.76
PLPL3
  
High negative correlations   
HBTS5
- 0.83
PLPL3
BEWZ39
- 0.8
HBTS5
BEWZ39
- 0.79
BTLG11
E1RI34
- 0.79
BTLG11
BEWZ39
- 0.79
ENGI11
PLPL3
- 0.78
BTLG11

Risk-Adjusted Indicators

There is a big difference between Gilead Stock performing well and Gilead Sciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Gilead Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Gilead Sciences Competitive Analysis

The better you understand Gilead Sciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Gilead Sciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Gilead Sciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
GILD34 ENGI11 BTLG11 PLPL3 HBTS5 PGCO34 E1RI34 C1AB34 ATMP3 BEWZ39
 1.20 
 262.19 
Gilead
 1.91 
 42.58 
Energisa
 0.40 
 96.50 
BTG
 2.57 
 13.99 
Plano
 2.65 
 30.08 
Companhia
 1.06 
 74.49 
Procter
 2.48 
 23.16 
Telefonaktiebolaget
 4.35 
 12.24 
Cable
 1.54 
 1.32 
ATMA
 0.53 
 53.26 
Ishares
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Not too volatile
Not too volatile
Very steady
Very steady
Not too volatile
Dangerous
Very steady
Market Performance
(90 Days Performance)
Solid
Very Weak
Very Weak
Modest
Very Weak
OK
OK
Good
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Low
About Average
Low
Low
Low
Quite High
About Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Fairly Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Cautious Hold
Sell
Hold
Strong Sell
Strong Sell
Strong Hold
Strong Buy
Strong Sell
Strong Sell
Current Ratio
3.76
1.65
2.78
5.68
0.51
0.79
N/A
1.86
0.41
N/A
Net Asset
63.17 B
54.77 B
N/A
1.27 B
1.32 B
117.21 B
305.61 B
6.95 B
1.77 B
N/A
Profit Margin
0.17
0.086
18.96
0.0763
0.068
0.18
0.069
0.22
-0.58
N/A
EBITDA
6.75 B
6.46 B
N/A
190.28 M
196.32 M
21.24 B
38.66 B
789.6 M
(21.6 M)
N/A
Operating Margin
0.4
0.21
62.59
0.0975
0.27
0.23
N/A
0.31
-0.37
N/A
Current Valuation
686.18 B
18.78 B
202.43 M
971.73 M
470.48 M
2.06 T
101.24 B
41.25 B
300.54 M
N/A
Price To Book
5.3
N/A
1.08
1.81
0.55
8.36
1.46
2.3
N/A
N/A
Five Year Return
N/A
2.94
N/A
N/A
2.94
N/A
N/A
N/A
N/A
N/A
Retained Earnings
N/A
N/A
N/A
N/A
260 M
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
N/A
N/A
N/A
79 M
N/A
N/A
N/A
N/A
N/A
Beta
0.41
0.66
0.65
-0.66
0.8
0.4
0.27
0.81
0.89
N/A
Number Of Employees
31
17.15 K
N/A
6
12
106 K
105.53 K
3.63 K
15.39 K
N/A
Shares Outstanding
2.49 B
N/A
1.65 M
198.26 M
5.95 M
33.03 B
6.66 B
1.16 B
26.71 M
N/A
Cash Flow From Operations
9.07 B
881.74 M
5.63 M
73.71 M
(80.77 M)
16.72 B
39.06 B
704.34 M
44.98 M
N/A
Annual Yield
0.0342
0.086
N/A
0.0386
0.0384
0.0262
0.0457
0.0136
N/A
N/A
Total Debt
25.18 B
19.31 B
N/A
347.45 M
173.49 M
22.85 B
22.24 B
3.8 B
200.39 M
N/A
Return On Equity
0.22
0.23
1.13
0.29
0.0216
0.32
0.16
0.21
-15.83
N/A
Z Score
13.2
N/A
N/A
2.2
N/A
45.0
2.4
3.6
N/A
N/A
Return On Asset
0.1
0.0655
2.33
0.0624
0.0204
0.0955
0.0592
0.0472
-0.11
N/A
Book Value Per Share
17.01
5.73
98.81
1.94
54.72
1.31
N/A
325.52
-10.3
N/A
Current Liabilities
N/A
N/A
N/A
N/A
102 M
N/A
N/A
N/A
N/A
N/A
Total Asset
63.17 B
54.77 B
N/A
1.27 B
1.32 B
117.21 B
305.61 B
6.95 B
1.77 B
N/A
Debt To Equity
117.0
239.0
N/A
1.33
0.21
54.4
N/A
2.38
2.31
N/A
Last Dividend Paid
2.92
0.67
0.32
0.16
N/A
3.61
N/A
11.1
N/A
N/A
Target Price
N/A
58.89
N/A
6.04
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
43.09
0.03
12.07
N/A
N/A
N/A
N/A
74.49
N/A
Market Capitalization
572.2 B
11.03 B
157.42 M
814.83 M
167.92 M
1.73 T
101.28 B
24.75 B
29.38 M
N/A
Price To Earning
28.35
78.94
98.94
4.69
312.5
102.83
N/A
0.19
N/A
N/A
Price To Earnings To Growth
0.71
0.7
N/A
N/A
N/A
4.98
1.89
N/A
N/A
N/A
Price To Sales
21.27
0.41
14.75
0.52
1.1
23.62
0.79
13.89
0.0385
N/A
Net Income
4.59 B
2.82 B
2.02 M
135.09 M
189.8 M
14.74 B
22.69 B
291.82 M
(136.28 M)
N/A
Earnings Per Share
9.63
1.38
1.08
0.5
1.21
2.15
1.44
1.56
-6.44
N/A
Shares Owned By Insiders
N/A
N/A
N/A
69.28
36.19
N/A
N/A
N/A
9.7
N/A
Revenue
27.28 B
26.8 B
10.67 M
1.27 B
266.95 M
80.19 B
232.31 B
1.61 B
1.05 B
N/A
Working Capital
N/A
N/A
N/A
N/A
(23 M)
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
28.36 B
435.34 M
N/A
186.95 M
55.87 M
9.82 B
N/A
448.96 M
1.84 M
N/A
Cash Per Share
22.39
1.36
N/A
1.37
8.71
3.92
N/A
74.36
1.35
N/A
Gross Profit
21.62 B
4.54 B
8.26 M
396.77 M
172.12 M
38.21 B
113.49 B
1.15 B
89.37 M
N/A
Day Typical Price
262.35
42.48
96.68
13.9
30.08
74.12
23.16
12.28
1.32
52.87
Accumulation Distribution
0.26
82308.96
493.12
54618.41
N/A
14.72
N/A
0.0097
379.1
16.65
Market Facilitation Index
0.0034
0.0
0.0
N/A
N/A
0.0012
N/A
0.12
0.0
0.0025
Daily Balance Of Power
6.5
0.597
(0.71)
0.6731
(9,223,372,036,855)
0.6842
(9,223,372,036,855)
4.25
0.5
0.1867
Period Momentum Indicator
3.12
0.8
(0.39)
0.35
(0.82)
0.78
(0.59)
0.51
0.02
0.28
Rate Of Daily Change
1.01
1.02
1.0
1.03
0.97
1.01
0.98
1.04
1.02
1.01
Day Median Price
262.43
42.43
96.78
13.86
30.08
73.94
23.16
12.3
1.32
52.67
Price Action Indicator
1.32
0.55
(0.47)
0.31
(0.41)
0.94
(0.29)
0.2
0.01
0.73
Coefficient Of Variation
385.76
(729.77)
(902.31)
859.21
(1,216)
1036.5
783.02
544.29
(156,251)
2879.05
Mean Deviation
0.9404
0.9978
0.5225
1.74
1.72
1.05
1.24
1.48
2.18
0.9638
Jensen Alpha
0.3662
(0.22)
(0.1)
0.1795
(0.35)
0.1573
0.2183
0.2931
(0.06)
0.0303
Total Risk Alpha
0.1482
(0.41)
(0.20)
(0.09)
(0.84)
(0.09)
(0.07)
0.0543
(0.54)
(0.17)
Sortino Ratio
0.1151
N/A
N/A
0.0633
N/A
0.0068
0.1003
0.1148
N/A
(0.06)
Downside Variance
5.33
N/A
N/A
3.41
N/A
1.53
2.07
6.18
N/A
1.82
Standard Deviation
1.52
1.35
0.7321
2.11
3.5
1.42
2.14
2.25
3.4
1.35
Kurtosis
7.46
0.5544
2.25
(0.62)
7.08
2.45
19.6
3.33
6.17
1.94
Potential Upside
2.49
2.44
0.9777
3.98
5.18
2.19
3.48
4.35
6.38
2.06
Treynor Ratio
2.51
(0.84)
(1.44)
0.499
(0.67)
(0.50)
0.6966
0.4319
(0.03)
0.6622
Maximum Drawdown
12.23
6.68
4.73
8.69
20.67
7.52
16.05
14.25
21.44
8.19
Variance
2.31
1.83
0.5359
4.45
12.24
2.02
4.57
5.08
11.55
1.82
Market Risk Adjusted Performance
2.52
(0.83)
(1.43)
0.509
(0.66)
(0.49)
0.7066
0.4419
(0.02)
0.6722
Risk Adjusted Performance
0.2031
(0.10)
(0.09)
0.0953
(0.06)
0.0784
0.104
0.147
0.0073
0.0309
Skewness
(0.10)
0.2438
0.4043
0.1632
(1.31)
0.8103
3.52
0.8811
1.71
0.3607
Semi Deviation
0.9477
N/A
N/A
1.64
N/A
1.12
0.8713
1.28
N/A
1.25
Information Ratio
0.1747
(0.23)
(0.29)
0.0554
(0.12)
0.0059
0.0676
0.1267
(0.04)
(0.06)
Value At Risk
(1.01)
(2.29)
(1.29)
(3.19)
(6.25)
(1.88)
(2.09)
(2.60)
(5.07)
(2.07)
Expected Short fall
(1.52)
N/A
N/A
(2.03)
N/A
(1.15)
(2.11)
(2.51)
N/A
(1.01)
Downside Deviation
2.31
N/A
N/A
1.85
N/A
1.24
1.44
2.49
N/A
1.35
Semi Variance
0.8981
N/A
N/A
2.7
N/A
1.25
0.7591
1.64
N/A
1.55

Gilead Sciences Competition Performance Charts

Five steps to successful analysis of Gilead Sciences Competition

Gilead Sciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Gilead Sciences in relation to its competition. Gilead Sciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Gilead Sciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Gilead Sciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Gilead Sciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Gilead Sciences position

In addition to having Gilead Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Sovereign ETFs Thematic Idea Now

Sovereign ETFs
Sovereign ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Gilead Stock

When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
How To Invest In Gilead
Details
Is Gilead Stock a good investment?
Details
What is Gilead Sciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Gilead Sciences Correlation with its peers.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY